EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Rationales of Cold Plasma Jet Therapy in Skin Cancer

Sander Bekeschus, Debora Singer, Gishan Ratnayake, Klaus Ruhnau, Kostya Ostrikov, Erik W Thompson

Experimental Dermatology · 2025-02 · 34 (2)

DOI: 10.1111/exd.70063 ↗

At a glance

Übersichtsarbeit in Experimental Dermatology, published online on 2025-02-19. Written by Sander Bekeschus and 5 co-authors. Institution: Department of Dermatology and Venerology, Rostock University Medical Center, Rostock, Germany. Major MEDLINE topics: Skin Neoplasms, Plasma Gases, Melanoma, Basal Cell Carcinoma. Cited 15 times so far (Crossref); 130 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Skin cancer affects millions of patients worldwide, and its incidence is increasing. Current therapies targeting skin tumour subtypes, such as basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma and actinic keratosis, vary in their degree of effectiveness and tolerability, motivating new research avenues on complementing treatment strategies. Cold medical gas plasma is a partially ionised gas operated at about body temperature and generates various reactive oxygen and nitrogen species simultaneously. A range of medical gas plasma devices has proven safe in thousands of patients and is an approved medical product for dermatology conditions, such as nonhealing wounds, in Europe and, more broadly, for clinical trials. Extending potential gas plasma applications in the field of dermato‐oncology is therefore plausible, especially in light of the strong preclinical evidence and early clinical data. This review summarises existing work on gas plasma treatment, focusing on approved jet plasmas in skin cancer and outlining central mechanisms and treatment concepts. It also provides a concrete perspective on integrating medical gas plasma treatment into existing skin cancer therapy schemes, encouraging translational scientists and clinicians to enable gas plasma‐assisted cancer care through clinical research.

Subjects

MeSH terms (MEDLINE)

Skin NeoplasmsPlasma GasesMelanomaBasal Cell CarcinomaCarcinoma, Squamous CellHumansKeratosis, Actinic

Author keywords

AKBCCSCCactinic keratosisbasal cell carcinomacombination therapiesmalignant melanomasquamous cell carcinomatumour wound

Substances

Plasma Gases

Authors and institutions

  • Department of Dermatology and Venerology, Rostock University Medical Center, Rostock, Germany.
  • ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany.
  • Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • neoplas MED, Greifswald, Germany.
  • School of Chemistry and Physics and Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia.
  • School of Biomedical Sciences and Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland, Australia.

Cite

APA

Bekeschus, S., Singer, D., Ratnayake, G., Ruhnau, K., Ostrikov, K., & Thompson, E. W. (2025). Rationales of Cold Plasma Jet Therapy in Skin Cancer. Experimental Dermatology, 34(2). https://doi.org/10.1111/exd.70063

Vancouver

Bekeschus S, Singer D, Ratnayake G, Ruhnau K, Ostrikov K, Thompson EW. Rationales of Cold Plasma Jet Therapy in Skin Cancer. Experimental Dermatology. 2025;34(2). doi:10.1111/exd.70063

BibTeX
@article{Bekeschus2025,
  author = {Bekeschus, Sander and Singer, Debora and Ratnayake, Gishan and Ruhnau, Klaus and Ostrikov, Kostya and Thompson, Erik W},
  title = {Rationales of Cold Plasma Jet Therapy in Skin Cancer},
  journal = {Experimental Dermatology},
  year = {2025},
  volume = {34},
  number = {2},
  doi = {10.1111/exd.70063}
}
Start for free →